Ro 31-8830: structure given in first source; derivative of Ro 31-8425 with in vivo anti-inflammatory activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5084 |
| CHEMBL ID | 95925 |
| SCHEMBL ID | 5036866 |
| MeSH ID | M0204556 |
| Synonym |
|---|
| CHEMBL95925 |
| 3-{2-[(dimethylamino)methyl]-1h,2h,3h,4h-pyrido[1,2-a]indol-10-yl}-4-(1-methyl-1h-indol-3-yl)-2,5-dihydro-1h-pyrrole-2,5-dione |
| bdbm2705 |
| bisindolylmaleimide deriv. 18b |
| 3-[8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methyl-3-indolyl)-1h-pyrrole-2,5-dione hydrochloride |
| ro 31-8830 |
| ro-31-8830 |
| 1h-pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1h-indol-3-yl)- |
| 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1h-indol-3-yl)-1h-pyrrole-2,5-dione |
| HMS3401G14 |
| HMS3401J16 |
| bim 11; bisindolylmaleimide xi, hcl |
| K00206 |
| HSCI1_000347 |
| NCGC00163696-01 |
| (s)-3-(8-(dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1h-pyrrole-2,5-dione hydrochloride |
| 131848-98-1 |
| SCHEMBL5036866 |
| NCGC00163696-04 |
| 3-{8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl}-5-hydroxy-4-(1-methyl-1h-indol-3-yl)-2h-pyrrol-2-one |
| DTXSID20927366 |
| 3-[8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione |
| nsc-767270 |
| nsc767270 |
| 1h-pyrrole-2,5-dione, 3-[8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methyl-1h-indol-3-yl)- |
| AKOS040749339 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 57.4571 | 0.1259 | 19.1169 | 125.8920 | AID2549; AID504841 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 37.6858 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) | IC50 (µMol) | 8.6000 | 0.0020 | 1.2409 | 9.0000 | AID1795421 |
| Protein kinase C beta type | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0420 | 0.0000 | 0.2164 | 1.1000 | AID1795420 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| mesoderm formation | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| protein phosphorylation | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| peptidyl-serine phosphorylation | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| cellular response to heat | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| negative regulation of TORC1 signaling | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protein kinase activity | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| protein serine/threonine kinase activity | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| AMP-activated protein kinase activity | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| cAMP-dependent protein kinase activity | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| protein binding | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| ATP binding | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| protein domain specific binding | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| protein serine kinase activity | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| acrosomal vesicle | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| nucleus | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| cytoplasm | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| mitochondrion | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| plasma membrane | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| neuromuscular junction | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| sperm flagellum | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| perinuclear region of cytoplasm | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| cAMP-dependent protein kinase complex | cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1795420 | PKC assay from Article 10.1021/jm00053a003: \\Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.\\ | 1993 | Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1 | Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction. |
| AID1795421 | PKA assay from Article 10.1021/jm00053a003: \\Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.\\ | 1993 | Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1 | Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.24) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||